A Multi-center, North American, Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease (Open-Hart)

Trial Profile

A Multi-center, North American, Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease (Open-Hart)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Pridopidine (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions
  • Acronyms OPEN-HART
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 28 Apr 2017 Results of exploratory analysis comparing subjects of Open-HART study with placebo controls of CARE-HD and 2CARE presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 01 Mar 2016 Planned primary completion date changed from 1 Jan 2020 to 1 Apr 2021 as reported by ClinicalTrials.gov record.
    • 01 Mar 2016 Planned End Date changed from 1 Jan 2021 to 1 May 2021 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top